Chikungunya

• EMA approval · 2026-08-24
  EMA Authorised: Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated) — Valneva Austria GmbH

  EMA has authorized Ixchiq, a live attenuated chikungunya virus vaccine (strain CHIKV LR2006-OPY1) by Valneva Austria GmbH.

• EMA approval · 2026-06-05
  EMA Authorised: Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated) — Valneva Austria GmbH

  EMA authorised Ixchiq (live attenuated chikungunya virus vaccine) for chikungunya virus indications.

• EMA approval · 2025-09-24
  EMA Authorised: Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated) — Valneva Austria GmbH

  The European Medicines Agency authorised Ixchiq, a live attenuated chikungunya virus vaccine (CHIKV LR2006-OPY1) developed by Valneva Austri…

• EMA approval · 2025-08-22
  EMA Authorised: Vimkunya (Chikungunya virus (CHIKV) virus-like particle (VLP) proteins (capsid protein (C) and envelope proteins E1 and E2) derived from CHIKV Senegal strain 37997 produced in human embryonic kidney cells by recombinant DNA technology, adsorbed on aluminium hydroxide, hydrated) — Bavarian Nordic A/S

  The EMA authorised Vimkunya for chikungunya. Vimkunya is a chikungunya virus-like particle vaccine produced in human embryonic kidney cells …

• EMA approval · 2025-01-31
  New Chikungunya vaccine for adolescents from 12 and adults

  EMA approved Vimkunya, a chikungunya vaccine, for adolescents aged 12 years and older and adults; the review was expedited due to public hea…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2024-05-31
  First vaccine to protect adults from Chikungunya

  EMA announced Ixchiq, the first chikungunya vaccine for adults, is being assessed under the OPEN framework to promote global public health.